DEF: INmune Bio Seeks Shareholder Approval for Option Repricing

INmune Bio Inc. is seeking stockholder approval to reprice certain outstanding stock options for current directors, executive officers, and employees to address retention and competitiveness concerns.

Summary

• A special meeting of stockholders will be held virtually on November 18, 2025, at 10:00 a.m. Eastern Time.
• The primary purpose is to approve the repricing of outstanding stock options granted under the company's 2017, 2019, and 2021 Stock Incentive Plans.
• Eligible options were granted between January 1, 2018, and January 22, 2025.
• If approved, the exercise price of eligible options will be reduced to the closing price of the company's common stock on the Nasdaq Capital Market on the date of the Special Meeting.
• All other terms and conditions of the eligible options, including vesting schedules, will remain unchanged.
• As of September 30, 2025, the closing price of common stock was $2.07 per share, rendering 100% of total outstanding stock options underwater (exercise price exceeded market price).
• The Board of Directors believes the repricing is necessary for employee retention, competitiveness, and to align employee interests with stockholders.
• A secondary proposal seeks approval to adjourn the Special Meeting if necessary to solicit additional proxies for the option repricing proposal.

Sentiment

Score: 3

Explanation: The sentiment is negative due to 100% of stock options being underwater, reflecting significant past stock price decline. However, the repricing proposal is a proactive measure to address employee retention and motivation, which is crucial for future success, thus preventing a lower score.

Positives

• Aims to improve employee retention and competitiveness by re-incentivizing staff whose options are currently underwater.
• Seeks to better align the interests of stock option holders (directors, executive officers, and employees) with those of the company's stockholders.
• The Board of Directors has determined the repricing is in the best interest of the company and its stockholders.

Negatives

• 100% of outstanding stock options were underwater as of September 30, 2025, indicating a significant decline in the company's stock price relative to grant prices.
• The repricing directly benefits current employees, executive officers, and directors, which could be perceived negatively by existing shareholders.
• Alternatives like substantially increasing cash compensation were deemed undesirable due to potential adverse effects on compensation expenses and cash flow.

Risks

• The market price for the company's common stock has historically been volatile, reflecting inherent risks and uncertainties in product candidate development.
• Failure to improve the prospects of Eligible Option holders receiving long-term value from their stock options could undermine their long-term commitment.
• Excluding executive officers and directors from the repricing could result in the loss of highly-valued contributors.
• Significant increases in cash compensation, as an alternative, would substantially increase compensation expenses and reduce cash flow from operations.

Future Outlook

The Board believes the Repricing will encourage increased alignment of interests of stock option holders with stockholders and their stake in long-term performance and success. It aims to retain experienced and talented personnel and re-incentivize those with underwater options, which is crucial for the company's future development as a clinical-stage pharmaceutical company.

Management Comments

• "The Board of Directors has determined that the Repricing is in our best interest and in the best interest of our stockholders."
• "Stock-based incentive compensation opportunities play a key role in our ability to recruit, motivate and retain qualified individuals."
• "Equity compensation most effectively links pay to performance as it encourages employees, directors and executive officers to work toward our success and aligns their interests with those of our stockholders."
• "We face significant competition for experienced and talented personnel with critical and high demand skills in our industry, and stock options are an important part of our incentive compensation."
• "Adverse changes in the market price of our common stock compared to the market practice of our common stock at the time of the grant of the Eligible Options could materially disrupt our efforts to retain the service of the Eligible Option holders."
• "When the market price of our common stock is significantly below the applicable exercise price of a stock option... a stock option holder is unlikely to exercise such stock option because there is a lower likelihood of financial gain... The Board of Directors believes such stock option holders may in turn be less incentivized to contribute to our long-term business goals."

Industry Context

As a clinical-stage pharmaceutical company, INmune Bio operates in an industry characterized by high volatility in stock prices due to the inherent risks and uncertainties of drug development. The need to reprice options reflects a common challenge in this sector where long development cycles and binary clinical trial outcomes can lead to significant stock price fluctuations, making original equity incentives less effective for retention and motivation when options go underwater. The company's emphasis on retaining 'experienced and talented personnel with critical and high demand skills' is typical for a biotech firm competing for specialized scientific and executive talent.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the repricing in the context of global benchmarks.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for increased dilution from repriced options, but also potential for improved long-term company performance due to enhanced employee retention and motivation. Voting on the proposal directly impacts their equity value and governance.
• **Employees, Executive Officers, and Directors**: Direct financial benefit from the repricing of underwater stock options, leading to increased motivation, retention, and alignment with company success.
• **Creditors**: No direct impact mentioned, but improved employee retention could indirectly support long-term operational stability.

Next Steps

• Stockholders are urged to vote on the Option Repricing Proposal and the Adjournment Proposal at the Special Meeting on November 18, 2025.
• The company will announce preliminary voting results at the Special Meeting.
• Final voting results will be published in a Current Report on Form 8-K within four business days following the Special Meeting.
• Stockholder proposals for the 2026 annual meeting proxy materials must be received by February 27, 2026.

Key Dates

Recommendation

The recommendation is 'hold' because while the repricing of 100% underwater options indicates past poor stock performance, the company is taking a necessary step to retain key talent and re-align incentives. This action, if approved, could stabilize the workforce and potentially contribute to future performance. However, the filing does not provide sufficient information on the company's operational or financial performance to warrant a 'buy' or 'sell' recommendation. Investors should monitor the impact of this repricing on employee morale and future business outcomes.

Keywords

Stock Option Repricing, Employee Retention, Executive Compensation, Corporate Governance, Shareholder Meeting, Nasdaq Capital Market, INmune Bio, Biotechnology, Pharmaceutical, Proxy Statement